Immunic 3Q 2026: EPS ($0.99) — 10-Q Summary

Immunic reported a net loss of $42.3M, up 65% YoY, with operating expenses rising 67%. R&D costs increased 20%, while G&A expenses surged 225% due to personnel costs. Top-line data from Phase 3 trials is expected in December 2026. According to the company, Phase 3 progressive MS trial initiation is ongoing, with first-patient-enrolled expected in the first half of 2027.

Original reporting
Published Nov 13, 2026, 12:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Immunic 3Q 2026: EPS ($0.99) — 10-Q Summary — source image
Decision brief

The 30-second read

$IMUXBearishMed
01

Why it matters

The earnings miss and expense increase are likely to depress the stock in the near term, though upcoming trial readouts could provide a catalyst.

02

Market read

Primary earnings disclosure for a micro‑cap biotech; short‑term downside risk with potential longer‑term upside from trial data.

03

What to watch

The company is advancing multiple Phase 3 trials, which could offset short-term earnings weakness if data are positive.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

Immunic filed its Form 10‑Q for Q3 2026, detailing financial results and trial timelines.

Company-level read

Ticker impact

$IMUXBearishHigh confidence
Context

Immunic reported a Q3 2026 net loss of $42.3M and EPS of -$0.99, widening from the prior quarter.

Expected impact

likely pressure as the market prices in the larger loss and expense surge

Evidence & confidence

Earnings miss and expense growth are fresh primary data that typically drive short-term price declines.

Market effects

Biotech sector may see modest pullback as a peer reports higher R&D spend and loss.

US-listed biotech stocks could face slight downside pressure.

Limited; impact confined to Immunic and closely related biotech peers.

Counterpoint

If the market overreacts to the loss, a bounce could occur on the upcoming Phase 3 trial data in December.

Key entities

  • Immunic, Inc.

    US‑listed biotech company reporting Q3 2026 results.

Related articles

$IMUXMedAI 8/10

Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update

IMMUNIC, INC. (IMUX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update – Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data Expected in December 2026 – – Initiatio

Med

Immunic Releases Q3 2026 Financial Results

Immunic Inc. reported a narrower Q3 2026 loss of $0.99 per share, down 25% from the prior year. The biotech company's net loss was $42.3M, attributed to R&D investments. Analysts remain bullish, with 9 buy and 1 hold rating. The company is developing therapies for chronic inflammatory and autoimmune diseases.

$IMUXHigh

Immunic shares fall 5% on third quarter earnings miss

Immunic Inc. (IMUX) reported a Q3 loss of $0.99 per share, missing estimates by $0.05. Shares fell 5.44% premarket. Net loss was $42.3M, up from $25.6M last year, due to higher operating expenses. The company expects top-line data from ENSURE-1 and ENSURE-2 trials in December 2026. Cash reserves are $132.0M, expected to last into late 2027.

$IMUXMedAI 8/10

EQS-News: Immunic AG: Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting

Immunic (IMUX) presented new clinical, biomarker, and preclinical data for vidofludimus calcium at MSToronto2026. Data showed durability of disability outcomes, neuroprotective effects, and reduced EBV-specific T-cell signatures. The company plans to initiate a Phase 3 program in progressive MS and expects top-line results from Phase 3 ENSURE trials by year-end 2026.